Guillain–Barré syndrome following coronavirus disease vaccine: First report from Nepal

ChAdOx1 nCoV-19 is an effective and well-tolerated coronavirus disease 2019 vaccine. However, rare cases of serious adverse events have been reported with it. We report a patient who did not have active or prior coronavirus disease 2019 infection, who developed Guillain–Barré syndrome 7 days followi...

Descripción completa

Detalles Bibliográficos
Autores principales: Luitel, Prajjwol, Poudel, Bibek, Upadhyay, Devansh, Paudel, Sujan, Tiwari, Nishan, Gajurel, Bikram Prasad, Karn, Ragesh, Rajbhandari, Reema, Shrestha, Aashish, Gautam, Niraj, Ojha, Rajeev
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130842/
https://www.ncbi.nlm.nih.gov/pubmed/35646371
http://dx.doi.org/10.1177/2050313X221100876
_version_ 1784713059963502592
author Luitel, Prajjwol
Poudel, Bibek
Upadhyay, Devansh
Paudel, Sujan
Tiwari, Nishan
Gajurel, Bikram Prasad
Karn, Ragesh
Rajbhandari, Reema
Shrestha, Aashish
Gautam, Niraj
Ojha, Rajeev
author_facet Luitel, Prajjwol
Poudel, Bibek
Upadhyay, Devansh
Paudel, Sujan
Tiwari, Nishan
Gajurel, Bikram Prasad
Karn, Ragesh
Rajbhandari, Reema
Shrestha, Aashish
Gautam, Niraj
Ojha, Rajeev
author_sort Luitel, Prajjwol
collection PubMed
description ChAdOx1 nCoV-19 is an effective and well-tolerated coronavirus disease 2019 vaccine. However, rare cases of serious adverse events have been reported with it. We report a patient who did not have active or prior coronavirus disease 2019 infection, who developed Guillain–Barré syndrome 7 days following the first dose of ChAdOx1 nCoV-19 vaccination. He was treated with intravenous immunoglobulin, with stabilization of the disease. Proper monitoring and prompt reporting of such cases are required to ensure the safety of the vaccine.
format Online
Article
Text
id pubmed-9130842
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-91308422022-05-26 Guillain–Barré syndrome following coronavirus disease vaccine: First report from Nepal Luitel, Prajjwol Poudel, Bibek Upadhyay, Devansh Paudel, Sujan Tiwari, Nishan Gajurel, Bikram Prasad Karn, Ragesh Rajbhandari, Reema Shrestha, Aashish Gautam, Niraj Ojha, Rajeev SAGE Open Med Case Rep Case Report ChAdOx1 nCoV-19 is an effective and well-tolerated coronavirus disease 2019 vaccine. However, rare cases of serious adverse events have been reported with it. We report a patient who did not have active or prior coronavirus disease 2019 infection, who developed Guillain–Barré syndrome 7 days following the first dose of ChAdOx1 nCoV-19 vaccination. He was treated with intravenous immunoglobulin, with stabilization of the disease. Proper monitoring and prompt reporting of such cases are required to ensure the safety of the vaccine. SAGE Publications 2022-05-20 /pmc/articles/PMC9130842/ /pubmed/35646371 http://dx.doi.org/10.1177/2050313X221100876 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Luitel, Prajjwol
Poudel, Bibek
Upadhyay, Devansh
Paudel, Sujan
Tiwari, Nishan
Gajurel, Bikram Prasad
Karn, Ragesh
Rajbhandari, Reema
Shrestha, Aashish
Gautam, Niraj
Ojha, Rajeev
Guillain–Barré syndrome following coronavirus disease vaccine: First report from Nepal
title Guillain–Barré syndrome following coronavirus disease vaccine: First report from Nepal
title_full Guillain–Barré syndrome following coronavirus disease vaccine: First report from Nepal
title_fullStr Guillain–Barré syndrome following coronavirus disease vaccine: First report from Nepal
title_full_unstemmed Guillain–Barré syndrome following coronavirus disease vaccine: First report from Nepal
title_short Guillain–Barré syndrome following coronavirus disease vaccine: First report from Nepal
title_sort guillain–barré syndrome following coronavirus disease vaccine: first report from nepal
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130842/
https://www.ncbi.nlm.nih.gov/pubmed/35646371
http://dx.doi.org/10.1177/2050313X221100876
work_keys_str_mv AT luitelprajjwol guillainbarresyndromefollowingcoronavirusdiseasevaccinefirstreportfromnepal
AT poudelbibek guillainbarresyndromefollowingcoronavirusdiseasevaccinefirstreportfromnepal
AT upadhyaydevansh guillainbarresyndromefollowingcoronavirusdiseasevaccinefirstreportfromnepal
AT paudelsujan guillainbarresyndromefollowingcoronavirusdiseasevaccinefirstreportfromnepal
AT tiwarinishan guillainbarresyndromefollowingcoronavirusdiseasevaccinefirstreportfromnepal
AT gajurelbikramprasad guillainbarresyndromefollowingcoronavirusdiseasevaccinefirstreportfromnepal
AT karnragesh guillainbarresyndromefollowingcoronavirusdiseasevaccinefirstreportfromnepal
AT rajbhandarireema guillainbarresyndromefollowingcoronavirusdiseasevaccinefirstreportfromnepal
AT shresthaaashish guillainbarresyndromefollowingcoronavirusdiseasevaccinefirstreportfromnepal
AT gautamniraj guillainbarresyndromefollowingcoronavirusdiseasevaccinefirstreportfromnepal
AT ojharajeev guillainbarresyndromefollowingcoronavirusdiseasevaccinefirstreportfromnepal

Ejemplares similares